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~ The American College Cardiology of Evaluation of 
Prsventlve Therapeutics (ACCEPT) Study,' 
Attainment of Goals for Comprehensive Risk 
Reductien in Patients With Coronary Disease in the 
US 
T,A, Pearson, T,D, Peters, D, Feury, RN for the ACCEPT Sfucty: University 
of Rochester, R~che~fet, N, Y; M,I, EJa~ett Ho.qp/f~ll, Cooppmtown, NY, USA 
The American College cf Cardiology and American Hosrt Assoclntlon have 
jointly published guld011noa for the comprehensive reduction in risk in pa- 
tients with coronary henri disease (CHD), but the extent to which they 
are Implemented In the U,S, Is poorly defined, To study this, the ACCEPT 
Study sele(~'tod a random sample o! 50 U,9, hospitals, and identified ~ 5OOO 
¢ton~osutivo p~tlonts {~dmlttod far first coronary bypass surgery (26%), first 
angiopl~sty (36%), acute myocardial infaretion (23%), or acids myocardial 
tschemla (15%), D~t~ were collected by medical record review to assess 
tnt0rventions eroded hl the hospital, nnd nn intenriew, physical oxamlnn- 
tton, and blood samptn was obtalnod ,~t tn,~st si~ months ~ftnr discha~e to 
essess which interventlena wore s~ibsoqtlentty IniIIsfed and whether goals 
were attained, Substantial pmv~ioncas of smoking, elevated blood pressure 
(~-t40/90 remHg,), nnd 0tnv¢lted LDL ehoiostnret (-.100 mg/dl) were still 
absented Six months nft0r discharge, Aspirin usage was widespread, but 
substantial numbom of patients were still not receiving beta blockers, ltpi,~. 
lowering agents, or estrogen tin women), Missed opportunities to implement 
the AHAIACC guidelines were identified at inpatient, ambulaton/care, and 
patient levels, Ft,lhor analysis of ACCEPT data will identily barriers which, 
it rectified, will serve to optimize cardlologlc are in those high risk patients. 
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~ European Action on Secondary Prevention by 
Intervention to Reduce Events 
David Wood. Nahonal Heart and Lung Institute, University of London: 
LondonUnifed, Kingdom 
European recomm~ndati0ns oncnmna~, prevention made iointly by the Eu- 
ropean Society of Cardiology, European Athorusclemsis Society and Euro- 
pean Society of Hypertension, proposed patients with coronary heart disease, 
or other major athnrosclerotic disease, as the top priority for action Yet a nine 
cmmtry European Survey (EureASPIRE), conducted under the auspices of 
the European Society at Cardiology, found recording and management at risk 
factors was less than optimal nnd considerable potential exists to reduce the 
risk at future morbidity and mortality. The survey was undertaken in the fol- 
lowing countries: Czech Republic. Finland, France, Germany, Hungary, Italy, 
Netherlands, Slovenia and Spain. 4866 patients records wore reviewed and 
3569 patients interviewed. In patients who had had coronary artery surgery 
or PTCA, or had been admitted to hospital with a myocardial infamtion or 
tschaemta without evidence o! intamtion the overall prevalence of smoking 
six or more months after discharge from hospital was 19%, 53% had hyper- 
tension, 44% elevated cholesterol and 18% had diabetes, Of those patients 
on antihypartnosi#o therapy only 59% had a SBP < mmRg. In the minority 
on lipid lowering therapy 39% had a total cholesterol > 5.5 mmol/L and 82% 
> 4.5 mmol/L Apart tram anti-platelet therapy, which was commonly (81%) 
used. there was considerable heterogeneity in the use of beta-blockers (35% 
to 78%), ACE inhibitors (17% to 46%) and lipid lowering drugs (22% to 42%) 
between centms. 
So the challenge in preventive cardiology is to bring about real lifestyle 
changes in our patients and to measure and manage, whom appropriate with 
drugs, blood pressure and lipids more effectively. In those with established 
coronary heart disease the use ut prophylactic drug therapies - asp.in, beta- 
blockers, cholesterol lowering agents, ACE inhibitors and anticoagulants - 
is also justified in selected patients to improve survival. To achieve all of this 
preventive cardiology requires professional recognition and resources. 
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/838-3 ~ Regional Variation In the Prsscrlptlon of Lipid 
Lowering Therapy In Patients With Coronary Artery 
Disease 
C.A. Suets, M. Chowdhury, D. Biggs. S. Boocuzzi, S.C. Smith. Jr.. 
R,J, Simpson, Jr, Medical Rev/ew ef No,"t,'~ Carolina, Merck& Co, and 
University of North Carolina at Chapel Hill, NC, USA 
It IS unclear why the prescdptlott of lipid Iowedng therapy fix) Is low In pati~lt~ 
(pts) with coronaq/artery disease (CAD), We examined an administrative 
d~t~ set containing ch~rt atJdlts on 12S,438 outpt~ with CAD (ICD9 code 
4t0-,.414) from 274 US ¢~rdioiogy ~nd multisgocietly practice~ to detopmirks 
the pradl~tom el the proscription o! rx, After oxolusion~ due to incomplete 
dntrt or I~ck of consent, 48,686 p~tlent ch~rte from t40 pmctces were 
nnslyzod. The melortty of praotlces, 7S%, were ca~!ology only practices, 
Geographically, 49% o! practices were in the South, 19% in the Nmtheast 
(NE), 18% in the Midwest (MW), and 14% in the West, The mean age at the 
cohort was 68 ± 0,1 yra and 36% were women, MI or CABG was documented 
in 49,8% of pts, Overall, 39% of pts were on Ix, Adiusting for age, gender, and 
t DL measurement, multivariate analysis indicated that documentation of MI 
or CABG,OR 1,36 (1,3~t ,43), cardiology only practice,OR 1,14 (1,08~1,19), 
and geographic region predicted the prescnption el ix, p ,~ 0,0t, Compared 
to the South, pts lrem the MW worn most likely to be treated.OR 1,38 
(1,30-,1,45), tallowed by the NE,OR 1,08 (1,03,-1,14), and the West,OR t ,05 
(0,99-..1,11), This suggests that region el the countnf and practice spemalty 
in addition to pt age and severity el !Unes.q influences pmscriptioe l lipid 
lowering therapy. 
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~ Lipid Lowering Therapy In CAD Patients at 
Academic Medical Centers: Undertreatment and 
Evidence of a Gender gap 
M Miller, RP, Byington, D, Hunninghako. C.D. Furberg, B. Pitt. PREVENT 
Investigators, University of Maryland, Baffimore MD~ Bowman Gray School 
Of Medina, Winston.Salem NC, Unw Minnesota, Mrnneapohs MN, Unff' 
Mchfgan, Ann Arbor MI, USA 
Randomized controlled studies have unequivocally demonstrated that lipid 
lowering therapy,0 (LLT) reduces cardiovasct,l~r vents in patients with coro- 
nary disease (CAD). We examined the prevalence of LLT use in PREVENT. 
a prospective randomized study of amledipine (Nonrasc" ) assessing vascu- 
lar events in CAD patients (n = 825). Women comprised 20% of the study 
cohort. Mean lipid levels am shown (Table). Although prevalence l LLT use 
increased yearly, a higher pementage at LLT use was always obse~.ed in 
men (p .: 0.06); 1993: 31% vs 26%, 1996: 56% vs 44%. The percentage 
of patients with LDL -:100 mg/dL was low in both men and women: 1994: 
17% vs 7%, 1996: 20% vs 14% These data reveal that at major US. and 
Canadian Academic Medical Centers. there is a gender gap in LLT use 
among CAD patients. Moreover, the vast majority of men and women receiv- 
ing LLT are not aggressively treated to the desirable LDL level (< 100 mg/dL) 
recommended by the National Cholesterol Education Program. These m- 
suits extend previous data linking gender differences in CAD management 
strategies and highlight he paucity of aggressive LLT in high risk patients. 
Mean Lipid Levels by Calendar Year 
Year TC LDL HDL TG % LOL .~ 100 
1994 219 135 49 181 15 
1995 214 129 50 185 15 
1996 207 125 45 185 19 
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[ -8 -~ Coronary Angiography Results Have Minimal Impact 
on Use of Lipid-Lowering Agents in Women: Pilot 
Phase Data From WISE 
V. Bittner, S.F. Kelsey, M. Olson, B. Gamble, W.J. Rogers, A. Boyette, 
D.L. Pakstis, K. Zell. University of Alabama at Birmingham, Alabama. UK 
Background: According to National Guidelines, intensity of lipid-lowering 
therapy should be m~:ched to risk status with an LDL cholesterol goal at 
< 100 mg/dl among those with CAD. 
Purpose: To assess the impact of coronary angiography results on use of 
lipid-lowering agents (LLAs) among women enrolled in WISE (The Women's 
Ischemia Syndrome Evaluation Study). 
Methods: WISE is a multicenter study designed to evaluate new diagnostic 
modalities among women who undergo angiography for suspected CAD. 
Lipids are measured at baseline and use of LLAs is ascertained at baseline 
and 6 weeks later. 
